Question

I am a breastfeeding mother and i want to know if it is safe to use HSDB 7316? Is HSDB 7316 safe for nursing mother and child? Does HSDB 7316 extracts into breast milk? Does HSDB 7316 has any long term or short term side effects on infants? Can HSDB 7316 influence milk supply or can HSDB 7316 decrease milk supply in lactating mothers?

Answer by DrLact: About HSDB 7316 usage in lactation

Most sources consider breastfeeding to be contraindicated during maternal high-dose antineoplastic drug therapy. The manufacturer recommends that mothers should not to breastfeed during treatment with HSDB 7316 and for one week after the last dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[1] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[2]

Alternate Drugs

Methotrexate(Low Risk)
Capecitabine(Dangerous)
Fluorouracil(Dangerous)
Rituximab(Low Risk)
Nivolumab(Unsafe)
Hydroxyurea(Low Risk)
Docetaxel(Dangerous)
Bevacizumab(Low Risk)
Etoposide(Dangerous)
Pazopanib(Unsafe)
Vinblastine(Dangerous)
Ipilimumab(Unsafe)
Bleomycin(Dangerous)
Doxorubicin(Dangerous)
Letrozole(Dangerous)
Cetuximab(Unsafe)
Vinorelbine(Dangerous)
Exemestane(Dangerous)
Carboplatin(Dangerous)
Dactinomycin(Dangerous)
Dacarbazine(Dangerous)
Cyclophosphamide(Dangerous)
Paclitaxel(Dangerous)
Erlotinib(Unsafe)
Trastuzumab(Unsafe)
Cladribine(Dangerous)
Cisplatin(Unsafe)
Dasatinib(Unsafe)
Busulfan(Dangerous)
Vincristine(Dangerous)
Imatinib(Unsafe)
Fluorouracil(Dangerous)
Tamoxifen(Dangerous)
Thioguanine(Dangerous)
Nilotinib(Unsafe)
Mitoxantrone(Dangerous)
Gemcitabine(Dangerous)
Alemtuzumab(Low Risk)
Rituximab(Low Risk)
Leflunomide(Dangerous)
Methotrexate(Low Risk)
Tocilizumab(Low Risk)
Auranofin(Low Risk)
Anakinra(Low Risk)
Abatacept(Low Risk)
Penicillamine(Low Risk)
Methotrexate(Low Risk)
Everolimus(Unsafe)
Methotrexate(Low Risk)
Leflunomide(Dangerous)
Fingolimod(Unsafe)
Sirolimus(Unsafe)
Cladribine(Dangerous)
Fluorouracil(Dangerous)
Pimecrolimus(Low Risk)
Gemcitabine(Dangerous)
Alemtuzumab(Low Risk)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.